Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Northera (Droxidopa) for Dysautonomia in Pediatric Survivors of Menkes Disease
NCT07398508Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Jun 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of droxidopa in dysautonomia (2 arms). Primary endpoint: Incidence of Serious Adverse Events at 10 weeks. Started Aug 2026; status: recruiting.
02
Drugs
droxidopa
03
Conditions
dysautonomia
Beyond the preview
Go deeper on NCT07398508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398508.